Business

OWC Pharmaceutical Research Corp Completes Formulation of Cannabinoid-Infused Topical Cream

OWC Pharmaceutical Research Corp Completes Formulation of Cannabinoid-Infused Topical Cream.

articleOwc Pharmaceutical Research CorpMarch 9, 20163/company/owc-pharmaceutical-research-corp/news/owc-pharmaceutical-research-corp-completes-formulation-of-cannabinoid-infused-topical-cream
OWC Pharmaceutical Research Corp Completes Formulation of Cannabinoid-Infused Topical Cream

About this update from Owc Pharmaceutical Research Corp

[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp Completes Formulation of Cannabinoid-Infused Topical Cream\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOWC Pharmaceutical Research Corp Completes Formulation of Cannabinoid-Infused Topical Cream\nCompany Plans To Begin Safety Tests for Its Topical Cream For The Treatment Of Psoriasis In the Second Quarter\nPR Newswire\nPETACH TIKVA, Israel, March 9, 2016\n\n\n\nPETACH TIKVA, Israel, March 9, 2016 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), (\"OWC\" or the \"Company\"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed development of a topical cream compound designed to ensure the effective delivery and dosage of its proprietary cannabinoid formulations. The cream was developed through a strategic alliance with Emilia Cosmetics Ltd., one of Israel's largest private label cosmetics manufacturers. \n\n\nThe Company has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval. This initial study will comprise multiple escalating doses to determine the safety, tolerability and pharmacokinetic profile of the medical grade cannabis cream in healthy volunteers. Once the initial study is completed, OWC intends to initiate studies at one of the biggest academic medical centers in Israel to determine the effect of the cream on psoriasis. \n\nPsoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, often causing a buildup of lesions that tend to burn and itch. While the underlying cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States, and ab...

More updates from Owc Pharmaceutical Research Corp